The prospective biomarker analysis of the phase II KEYNOTE-158 study revealed that high tTMB was correlated with clinical benefit (ORR and OS) with pembrolizumab as later-line treatment in various tumor types, including SCLC [57]. This evidence concerns the gene TMEM200B and neoplasm.